Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
CJCorey J. LangerSMShirish M. GadgeelHBHossein BorghaeiVAVassiliki A. PapadimitrakopoulouAPAmita Patnaik
University of Pennsylvania · The Barbara Ann Karmanos Cancer Institute · +18 more institutions
Indexed incrossref
Abstract
No abstract available for this paper.
Citation impact
1,388
total citations
- FWCI
- 105.02
- Percentile
- 100%
- References
- 29
Citations per year
Authors
19- CJCorey J. LangerCorresponding
University of Pennsylvania
- SMShirish M. Gadgeel
The Barbara Ann Karmanos Cancer Institute, Wayne State University
- HBHossein Borghaei
Fox Chase Cancer Center
- VAVassiliki A. Papadimitrakopoulou
The University of Texas MD Anderson Cancer Center
- APAmita Patnaik
South Texas Accelerated Research Therapeutics
Topics & keywords
Topics
Keywords
- Pemetrexed
- Pembrolizumab
- Carboplatin
- Medicine
- Internal medicine
- Oncology
- Lung cancer
- Chemotherapy
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.